Cargando…
The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies
This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that inc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751336/ https://www.ncbi.nlm.nih.gov/pubmed/29258183 http://dx.doi.org/10.3390/ijms18122735 |
_version_ | 1783289928008859648 |
---|---|
author | Fastrès, Aline Felice, Florence Roels, Elodie Moermans, Catherine Corhay, Jean-Louis Bureau, Fabrice Louis, Renaud Clercx, Cécile Guiot, Julien |
author_facet | Fastrès, Aline Felice, Florence Roels, Elodie Moermans, Catherine Corhay, Jean-Louis Bureau, Fabrice Louis, Renaud Clercx, Cécile Guiot, Julien |
author_sort | Fastrès, Aline |
collection | PubMed |
description | This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality. More recent work has highlighted the interaction between the lung microbiome and the innate immune system in IPF, strengthening the argument for the role of both host and environment interaction in disease pathogenesis. Existing published data suggesting that the lung microbiome may represent a therapeutic target, via antibiotic administration, immunization against pathogenic organisms, or treatment directed at gastroesophageal reflux. Taken altogether, published literature suggests that the lung microbiome might serve in the future as a prognostic biomarker, a therapeutic target, and/or provide an explanation for disease pathogenesis in IPF. |
format | Online Article Text |
id | pubmed-5751336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-57513362018-01-08 The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies Fastrès, Aline Felice, Florence Roels, Elodie Moermans, Catherine Corhay, Jean-Louis Bureau, Fabrice Louis, Renaud Clercx, Cécile Guiot, Julien Int J Mol Sci Review This review focuses on the role of the lung microbiome in idiopathic pulmonary fibrosis. Although historically considered sterile, bacterial communities have now been well documented in lungs both in healthy and pathological conditions. Studies in idiopathic pulmonary fibrosis (IPF) suggest that increased bacterial burden and/or abundance of potentially pathogenic bacteria may drive disease progression, acute exacerbations, and mortality. More recent work has highlighted the interaction between the lung microbiome and the innate immune system in IPF, strengthening the argument for the role of both host and environment interaction in disease pathogenesis. Existing published data suggesting that the lung microbiome may represent a therapeutic target, via antibiotic administration, immunization against pathogenic organisms, or treatment directed at gastroesophageal reflux. Taken altogether, published literature suggests that the lung microbiome might serve in the future as a prognostic biomarker, a therapeutic target, and/or provide an explanation for disease pathogenesis in IPF. MDPI 2017-12-16 /pmc/articles/PMC5751336/ /pubmed/29258183 http://dx.doi.org/10.3390/ijms18122735 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Fastrès, Aline Felice, Florence Roels, Elodie Moermans, Catherine Corhay, Jean-Louis Bureau, Fabrice Louis, Renaud Clercx, Cécile Guiot, Julien The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
title | The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
title_full | The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
title_fullStr | The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
title_full_unstemmed | The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
title_short | The Lung Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies |
title_sort | lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751336/ https://www.ncbi.nlm.nih.gov/pubmed/29258183 http://dx.doi.org/10.3390/ijms18122735 |
work_keys_str_mv | AT fastresaline thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT feliceflorence thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT roelselodie thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT moermanscatherine thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT corhayjeanlouis thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT bureaufabrice thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT louisrenaud thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT clercxcecile thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT guiotjulien thelungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT fastresaline lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT feliceflorence lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT roelselodie lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT moermanscatherine lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT corhayjeanlouis lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT bureaufabrice lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT louisrenaud lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT clercxcecile lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies AT guiotjulien lungmicrobiomeinidiopathicpulmonaryfibrosisapromisingapproachfortargetedtherapies |